Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this retrospective pharmacovigilance study, researchers analyzed over 7,900 adverse event reports related to aromatase inhibitors, identifying common side effects and toxicological mechanisms to highlight potential safety concerns in treating postmenopausal hormone receptor-positive breast cancer.

This study reported that after 7.5 months of treatment, topical Alfatradiol significantly increased anagen hair rates in women and men with androgenetic alopecia, with minimal side effects.

This study observed that most pediatric patients with alopecia areata experienced some hair regrowth after treatment with topical JAK inhibitors, and the formulations were generally well-tolerated with mild lab abnormalities in some cases.

This abstract introduces baricitinib as an approved treatment for adults with severe alopecia areata in the US, Europe, and Japan, but does not report any specific study results or findings.

This study diagnosed an 11-year-old girl with initial androgenetic alopecia and monilethrix after observing unique hair shaft abnormalities and skin conditions, unlike her affected parents.

The researchers reported that the petroleum ether extract of Cuscuta reflexa may promote hair growth in testosterone-induced alopecia in mice by inhibiting the enzyme 5α-reductase.

This study identified compounds 11d and 11k as potential dual 5α-reductase inhibitors and AR antagonists with significant anti-proliferative effects on prostate cancer cell lines, suggesting they may offer therapeutic value.

In this case report, a 37-year-old patient with APECED showed significant clinical improvement, including hair regrowth and resolution of skin issues, after 11 months of treatment with ruxolitinib, highlighting the potential of JAK inhibitors in managing this complex autoimmune disease.

This study reported that clascoterone cream reduced inflammatory and noninflammatory acne lesions in a trial with 1440 white males and non-pregnant females, showing it was well tolerated in these participants.

This report describes a 17-year-old woman who experienced severe anagen effluvium after DRESS syndrome but achieved full recovery in two months with topical minoxidil.

This study outlines treatment strategies for autoimmune alopecia areata, detailing that while mild cases may resolve on their own, severe cases often require intervention, with new JAK inhibitors like baricitinib and ritlecitinib emerging as promising treatments for those not responding to traditional therapies.

This study found that the ALAVAX complex, containing 5-ALA and GHK peptide, may increase hair count in male pattern hair loss patients over 6 months without adverse events.

This review discusses the condition alopecia areata and summarizes its available treatments, mentioning three recently approved Janus kinase inhibitors, but reports no new clinical results.

This study demonstrated that an ethanol extract of Connarus semidecandrus Jack showed potential anti-androgenic alopecia effects in a testosterone-induced model, suggesting a possible treatment option for hair loss.

This study reports that the metanephrine content was significantly higher in patients with alopecia areata compared to those without the condition.

This review examines the potential roles of azathioprine and methotrexate in treating alopecia areata, concluding that both can be effective as monotherapy or in combination therapy.

In this phase 2a study of adults with alopecia areata, researchers observed that ritlecitinib treatment did not result in significant differences in brainstem auditory evoked potential changes or axonal swelling compared to placebo, suggesting the dog toxicity findings may not be clinically relevant in humans.

In this study, Ritlecitinib was reported as a newly approved treatment for alopecia areata that can be used in patients aged 12 and older; after 24 weeks, it resulted in 80% or more scalp hair coverage in treated patients compared to a placebo.

This study used an in silico/in vitro approach to identify potential inhibitors of the enzyme SRD5A2, finding that the androgen receptor modulator MK-0773 is a moderate inhibitor, although it does not act as a covalent inhibitor like finasteride.

In this study, ALRV5XR treatment significantly increased terminal hair density in men with androgenetic alopecia after 24 weeks, while also decreasing vellus hair density, and was well tolerated without adverse events, suggesting its potential efficacy over standard therapies.

This study confirmed known adverse events and identified new ones related to ixekizumab, offering preliminary safety insights for its clinical use, but noted limitations such as potential underreporting and confounding factors in the spontaneous adverse event reporting systems.

In this study, the application of topical cetirizine 1% once daily for four months in Egyptian male patients with androgenetic alopecia led to a significant increase in terminal hairs and improved hair diversity, with promising safety and efficacy outcomes.

This study reported that ritlecitinib was prescribed to a diverse group of patients with severe alopecia areata in the first 10 months after FDA approval, indicating its potential role in AA management.

This study reports that topical ruxolitinib failed to induce hair growth in a 66-year-old patient with alopecia areata, highlighting the need to explore factors affecting treatment response and compare topical vs oral administration outcomes.

In this case report, a 41-year-old man with moderate androgenic alopecia showed an increase in hair density and improvements in hair characteristics after using Zimmer aqueous spray containing Zimmer herbal extract powder for 3 months, suggesting its potential as an alternative treatment for hair loss.

In this study, ALRV5XR significantly increased hair regrowth in women with androgenetic alopecia or telogen effluvium, with no adverse events reported.

This abstract reports preliminary data on the antidepressant reboxetine, noted for its different mode of action, discussed at a major psychiatry conference; it provides no new research findings.

This correspondence discusses clascoterone as a potential new treatment for androgenetic alopecia but reports no clinical results.

No results are provided in this article as it lacks an available abstract, making it unclear what effects apremilast and tofacitinib have in a humanized mouse model of alopecia areata.